On 23 February, Gilead Sciences announced its $7.8bn acquisition of Arcellx, primarily to secure rights to anitocabtagene autoleucel (anito-cel), an autologous anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) multiple myeloma (MM). This follows Kite Pharma’s, a Gilead company, expansion of its Arcellx agreement in January 2023, demonstrating increasing confidence in Arcellx’s pipeline.
CAR T-cell therapies for MM, though promising a convenient one-time infusion and improved progression-free survival (PFS) rates compared to conventional options, have yet to achieve significant market share due to safety concerns, high cost, and lengthy manufacturing timelines. Anito-cel received fast-track designation on 28 February 2026, after strong results in the iMMagine-1 trial for R/R MM patients treated with at least three prior regimens. GlobalData projects anito-cel sales reaching $658m by 2032 across eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, China), compared to Johnson & Johnson’s Carvykti (ciltacabtagene autoleucel) at $6.3bn and Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) at $1.6bn. Gilead’s confidence is evident in the launch of Phase III trials, iMMagine-2 and iMMagine-3, for earlier lines of therapy, with a 76% likelihood of approval and an ongoing Phase II trial as a first-line therapy. If successful, anito-cel could claim a larger market share of the patient segment than Carvykti, which is already approved for second- and third-line MM.
While Carvykti shows a higher efficacy than Abecma, it also has higher rates of severe cytokine release syndrome (CRS) and delayed neurotoxicity, the main adverse events associated with CAR T-cell therapies. In comparison, anito-cel has demonstrated similar efficacy to Carvykti, with severe CRS and neurotoxicity rates significantly lower than those of Abecma. Manufacturing speed is also an advantage for anito-cel, which leverages Kite’s infrastructure for a 17-day turnaround, faster than the 30-day benchmark for its competitors. This efficiency stems from its compact D-domain binder, promoting stable expression and reduced toxic "tonic signalling," which supports improved safety and higher manufacturing success rates. These factors position anito-cel to likely offer a cheaper T-cell therapy and improved patient experience.
While anito-cel holds strong potential, risks include scaling manufacturing capacity to meet demand while ensuring consistent supply chains and patient access. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly requiring robust, mature overall survival (OS) and long-term safety data, particularly for drugs seeking accelerated approval based on surrogate endpoints or early-phase results. Gilead appears well-positioned to pursue accelerated approval for anito-cel, supported by strong Phase II data, the clear justification of surrogate endpoints, and the confirmatory Phase III iMMagine-3 trial, which is already recruiting. However, there is still a threat that anito-cel’s indication could be restricted or revoked if confirmatory results disappoint or are delayed. Meanwhile, payer dynamics are also shifting, as reimbursement criteria are becoming more stringent due to the high cost and growing number of approved CAR-T therapies, requiring distinct advantages both clinically and economically across the treatment landscape for approval.
Beyond anito-cel, Arcellx adds to Gilead’s robust immuno-oncology portfolio, with cell therapies in development for MM, hepatocellular carcinoma, leukaemia, and small-cell lung cancer. Kite’s success with Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), and its established network of authorised treatment centres, is likely to support commercial launches for anito-cel and other pipeline products.
Gilead’s acquisition of Arcellx represents a strategic investment in next-generation CAR T-cell therapies, highlighting strong confidence in anito-cel’s clinical promise and a commitment to immuno-oncology leadership. Combining Gilead’s commercial strengths with Kite’s manufacturing expertise positions anito-cel for competitive advantage, but overcoming regulatory and payer headwinds will be essential for realising its potential. The coming years will be pivotal in confirming whether anito-cel can both transform MM care and reinforce Gilead’s leadership in cell therapy.
